Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma
Autor: | Tiffany Sara Liu, Leslie M. Niziol, Miguel A. Materin, Cem Ozgonul, Zeynep Gursel Ozkurt, David C. Musch, Naziha Slimani, Hakan Demirci |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Adolescent Kaplan-Meier Estimate Disease-Free Survival Metastasis Cohort Studies 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine International Classification of Diseases Risk Factors Internal medicine medicine Humans Stage (cooking) Fluorescein Angiography Neoplasm Metastasis Melanoma Survival analysis Cancer staging Aged Neoplasm Staging Probability Retrospective Studies Aged 80 and over business.industry Choroid Neoplasms Gene Expression Profiling Ciliary Body Cancer Retrospective cohort study Middle Aged medicine.disease United States Neoplasm Proteins Ophthalmology 030104 developmental biology 030221 ophthalmology & optometry Female business hormones hormone substitutes and hormone antagonists Tomography Optical Coherence Cohort study |
Zdroj: | American journal of ophthalmology. 195 |
ISSN: | 1879-1891 |
Popis: | PURPOSE To evaluate the prognostication of choroidal melanoma (CM) by the gene expression profiling (GEP) test. DESIGN Cohort study. METHODS Retrospective review of 293 CM patients from 2 centers. RESULTS Of 293 patients, 132 (45%) were class 1A by GEP, 63 (22%) were class 1B, and 98 (33%) were class 2. Class 2 tumors had more ciliary body involvement and greater largest basal dimension (LBD), and were thicker. GEP results and increasing LBD were independently predictive of time to metastasis. Kaplan-Meier survival analysis estimated the probability of 3-year metastasis-free survival (MFS) of 0.99 in class 1A, 0.90 in class 1B, and 0.60 in class 2. The probability of 3-year MFS was 0.49 in class 2 patients with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm, 0.89 in class 1B with LBD ≥ 12 mm vs 0.93 in those with LBD < 12 mm, and 0.99 in class 1A with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm. In American Joint Committee on Cancer (AJCC) stage I CMs, the probability of 3-year MFS was 1.0 for class 1A and 1B, and 0.79 for class 2. In stage II CMs, the probability of 3-year MFS was 0.99 for class 1A, 0.89 for class 1B, and 0.61 for class 2. In stage III CM, the probability of 3-year MFS was 1.0 for class 1A, 0.60 for class 1B, and 0.41 for class 2. CONCLUSIONS GEP testing provided significant prognostic information for CM. Class 2 tumors with LBD ≥ 12 mm and class 2 and 1B tumors with AJCC stage III showed significantly worse prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: |